Tyzeka vs Hepsera, Part Two (allow time for image to load):
#msg-11594768 showed data from the first 24 weeks of the phase-3b head-to-head study of Tyzeka (telbivudine) vs Hepsera (adefovir). The result: Tyzeka won easily, logging a mean viral-load reduction of 6.30 logs vs 4.97 logs for Hepsera at 24 weeks.
At 24 weeks, half of the Hepsera patients in the trial were switched to Tyzeka and thus there were three arms: Tyzeka for 52 weeks, Hepsera for 52 weeks, and the switch arm consisting of Hepsera for 24 weeks followed by Tyzeka fro 28 weeks.
The chart above shows the % of patients in each arm with undetectable virus at each time point.
Market Data 
Markets 
AI
